Literature DB >> 16393464

Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats.

Jie Wan1, Lena Ernstgård, Byoung J Song, Susan E Shoaf.   

Abstract

Earlier data showed that men fasted for 38 h had a reduced rate of chlorzoxazone metabolism, suggesting a decreased level of cytochrome P450 2E1 (CYP2E1). In contrast, the level of CYP2E1 in fasted rats had been shown to be elevated. In this study, we have investigated whether chlorzoxazone metabolism in fasted rats was changed by determining the pharmacokinetics of chlorzoxazone and its metabolite, 6-hydroxychlorzoxazone (6-OHCZ), as a CYP2E1 probe, and by measuring liver CYP2E1 using immunoblot techniques. Chlorzoxazone was administered by gavage (50 mg kg(-1)) or intravenously (25 mg kg(-1)) to control (nine for oral and three for intravenous) and 24 h-fasted (nine for oral and four for intravenous) male Sprague-Dawley rats. Following sampling of blood through a jugular vein cannula, chlorzoxazone and 6-OHCZ plasma concentrations were measured by HPLC with UV detection. Pharmacokinetic parameters for chlorzoxazone and 6-OHCZ in each treatment group were determined by model fitting and non-compartmental analysis. In parallel with the increased liver CYP2E1 level, the elimination of chlorzoxazone and 6-OHCZ was significantly increased in fasted rats in the oral and the intravenous study. A multiple analysis of variance covariance analysis and a multiple regression analysis revealed a significant correlation between 1/t(1/2) and CYP2E1 level and aniline hydroxylase activity. However, the correlation between 1/t(1/2) and pentoxyresorufin O-dealkylase, ethoxyresorufin O-dealkylase and erythromycin N-demethylase was not significant. Therefore the contribution of other P450s to chlorzoxazone metabolism seemed to be minor in the concentration range that we tested. In conclusion, fasting rats for 24 h caused a measurable induction of CYP2E1, which produced a significant increase in the rate of chlorzoxazone metabolism and elimination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393464      PMCID: PMC1388188          DOI: 10.1211/jpp.58.1.0007

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  38 in total

1.  Cytochrome P4502E1 inducibility and hydroxyethyl radical formation among alcoholics.

Authors:  I Dupont; D Lucas; P Clot; C Ménez; E Albano
Journal:  J Hepatol       Date:  1998-04       Impact factor: 25.083

2.  Toxicokinetic interactions between orally ingested chlorzoxazone and inhaled acetone or toluene in male volunteers.

Authors:  L Ernstgård; E Gullstrand; G Johanson; A Löf
Journal:  Toxicol Sci       Date:  1999-04       Impact factor: 4.849

3.  Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans.

Authors:  M G Emery; C Jubert; K E Thummel; E D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

4.  Acetone catabolism by cytochrome P450 2E1: studies with CYP2E1-null mice.

Authors:  F Y Bondoc; Z Bao; W Y Hu; F J Gonzalez; Y Wang; C S Yang; J Y Hong
Journal:  Biochem Pharmacol       Date:  1999-08-01       Impact factor: 5.858

5.  Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes.

Authors:  K J Woodcroft; R F Novak
Journal:  Chem Biol Interact       Date:  1997-11-06       Impact factor: 5.192

6.  Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans.

Authors:  D Lucas; R Ferrara; E Gonzalez; P Bodenez; A Albores; M Manno; F Berthou
Journal:  Pharmacogenetics       Date:  1999-06

7.  Depression of glutathione content, elevation of CYP2E1-dependent activation, and the principal determinant of the fasting-mediated enhancement of 1,3-dichloro-2-propanol hepatotoxicity in the rat.

Authors:  J R Fry; D Sinclair; C H Piper; S L Townsend; N W Thomas
Journal:  Food Chem Toxicol       Date:  1999-04       Impact factor: 6.023

8.  Changes in rat liver cytochrome P450 enzymes by atrazine and simazine treatment.

Authors:  N Hanioka; H Jinno; T Tanaka-Kagawa; T Nishimura; M Ando
Journal:  Xenobiotica       Date:  1998-07       Impact factor: 1.908

9.  Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats.

Authors:  L Chen; C S Yang
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

10.  Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes.

Authors:  D L Kroetz; P Yook; P Costet; P Bianchi; T Pineau
Journal:  J Biol Chem       Date:  1998-11-20       Impact factor: 5.157

View more
  5 in total

1.  KCa channels as therapeutic targets in episodic ataxia type-2.

Authors:  Karina Alviña; Kamran Khodakhah
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.

Authors:  Karina Alviña; Kamran Khodakhah
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

3.  Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.

Authors:  Sebastian Trousil; Patrizia Lee; Robert J Edwards; Lynn Maslen; Jingky P Lozan-Kuehne; Ramya Ramaswami; Eric O Aboagye; Stephen Clarke; Christopher Liddle; Rohini Sharma
Journal:  Br J Pharmacol       Date:  2019-08-05       Impact factor: 8.739

Review 4.  K(Ca)2 channels: novel therapeutic targets for treating alcohol withdrawal and escalation of alcohol consumption.

Authors:  Patrick J Mulholland
Journal:  Alcohol       Date:  2012-03-30       Impact factor: 2.405

5.  Toxicological Implications of Mitochondrial Localization of CYP2E1.

Authors:  Jessica H Hartman; Grover P Miller; Joel N Meyer
Journal:  Toxicol Res (Camb)       Date:  2017-03-14       Impact factor: 3.524

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.